BT In The News
- May 24, 2017 - Boston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty
- June 24, 2016 - Independence Blue Cross (IBX) Issues New Coverage Policy in Pennsylvania and New Jersey
- February 1, 2016 - Tufts Health Plan Provides Coverage for First Device-Based Procedure to Treat Severe Asthma
- June 9, 2015 - Boston Scientific Bronchial Thermoplasty Treatment Recognized by American College of Allergy, Asthma and Immunology
- September 4, 2013 - The Journal of Allergy and Clinical Immunology Publishes Bronchial Thermoplasty Data Demonstrating Sustained Reduction in Severe Asthma Attacks Over Five Years
The Alair™ Bronchial Thermoplasty System is indicated for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting beta-agonists.
As with any procedure, there are risks, and individual results may vary. The most common adverse event of BT is a temporary worsening of respiratory-related symptoms. These events typically occur within one day of the BT procedure and usually resolve within a week with standard care. There is a small risk (3.4% per procedure) that symptoms may require hospitalization.2